Факторы риска рецидива при аллогенной трансплантации у детей, подростков и молодых взрослых с острым лимфобластным лейкозом
Известно, что после аллогенной трансплантации гемопоэтических клеток (алло-ТГСК) от HLAидентичного сиблинга или неродственного донора у 20‒25 % пациентов с острыми лейкозами наблюдается рецидив основного заболевания.Цель исследования – проанализировать влияние различных факторов на частоту возникновения рецидивов после алло-ТГСК у пациентов с острым лимфобластным лейкозом.Изучено влияние таких факторов, как пол и возраст донора на момент трансплантации, пол и возраст реципиента на момент трансплантации, вид и количество предшествующих ТГСК рецидивов, вид кондиционирования, тип трансплантации, источник стволовых клеток, параметры трансплантата, наличие или отсутствие острой (оРТПХ) или хронической (хрРТПХ) реакции трансплантат против хозяина, наличие KIR-аллореактивности естественных киллеров пары донор/реципиент.Установлено, что возраст пациентов менее 4 лет на момент трансплантации (p = 0,0042), время возникновения рецидива (очень ранний и ранний рецидив) (p = 0,0047), отсутствие оРТПХ (p = 0,0183) или хрРТПХ (p = 0,0384) являются факторами, ассоциированными с риском развития рецидива после алло-ТГСК.
1. Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation / M. Miano [et al.] // Bone Marrow Transplant. ‒ 2007. ‒ Vol. 39, N 2. ‒ P. 89‒99. https://doi.org/10.1038/sj.bmt.1705550
2. Stem-Cell Transplantation in Children with Acute Lymphoblastic Leukemia: A Prospective International Multicenter Trial Comparing Sibling Donors with Matched Unrelated Donors ‒ The ALL-SCT-BFM-2003 Trial / С. Peters [et al.] // J. Clin. Oncol. ‒ 2015. ‒ Vol. 33, N 11. ‒ P. 1265‒1273. https://doi.org/10.1200/JCO.2014.58.9747
3. Pui, C-H. Acute lymphoblastic leukemia / C. H. Pui, W. E. Evans // N. Engl. J. Med. – 1998. – Vol. 339, N 9. ‒ P. 605–615. https://doi.org/10.1056/NEJM199808273390907
4. NCI first international workshop on the biology, prevention and treatment of relapse after allogeneic hematopoietic cell transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies / E. P. Alyea [et al.] // Biol. Blood Marrow Transplant. – 2010. – Vol. 16, N 8. ‒ P. 1037–1069. https://doi.org/10.1016/j.bbmt.2010.04.004
5. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts / S. Chiaretti [et al.] // Haematologica. – 2013. – Vol. 98, N 11. ‒ P. 1702–1710. https://doi.org/10.3324/haematol.2012.080432
6. Prognostic index for relapsed acute leukemia after allogeneic stem cell transplant / K. Matsumoto [et al.] // Leuk. Lymphoma. – 2014. – Vol. 55, N 12. ‒ P. 2808–2812. https://doi.org/10.3109/10428194.2014.896004
7. Monitoring mixed lineage leukemia expression may help identify patients with mixed lineage leukemia–rearranged acute leukemia who are at high risk of relapse after allogeneic hematopoietic stem cell transplantation / J. Liu [et al.] // Biol. Blood Marrow Transplant. – 2014. – Vol. 20, N 7. ‒ P. 929–936. https://doi.org/10.1016/j.bbmt.2014.03.008
8. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children’s Oncology Group and the Center for International Blood and Marrow Transplant Research / M. Eapen [et al.] // Blood. – 2006. – Vol. 107, N 12. ‒ P. 4961–4967. https://doi.org/10.1182/blood-2005-12-4942
9. Improvement of the outcome of relapsed or refractory acute lymphoblastic leukemia in children using a risk-based treatment strategy / F. Ceppi [et al.] // PLoS ONE. – 2016. – Vol. 11, N 9. – P. e0160310. https://doi.org/10.1371/journal.pone.0160310
10. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome / M. B. Tomblyn [et al.] // J. Clin. Oncol. – 2009. – Vol. 27, N 22. ‒ P. 3634–3641. https://doi.org/10.1200/JCO.2008.20.2960
11. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission / D. I. Marks [et al.] // Biol. Blood Marrow Transplant. – 2006. – Vol. 12, N 4. ‒ P. 438–453. https://doi.org/10.1016/j.bbmt.2005.12.029
12. Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience / A. M. Willasch [et al.] // Bone Marrow Transplant. – 2017. – Vol. 52, N 2. ‒ P. 201–208. https://doi.org/10.1038/bmt.2016.224
13. Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention / F. Ceppi [et al.] // Expert Rev. Hematol. – 2015. – Vol. 8, N 1. ‒ P. 57‒70. https://doi.org/10.1586/17474086.2015.978281
14. Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse / J. C. Beck [et al.] // Bone Marrow Transplant. – 2011. – Vol. 46, N 7. ‒ P. 950–955. https://doi.org/10.1038/bmt.2010.217
15. New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL / M. A. Pulsipher [et al.] // Bone Marrow Transplant. – 2014. – Vol. 49, N 10. ‒ P. 1259‒1265. https://doi.org/10.1038/bmt.2014.114
16. The graft-versus-leukaemia effect in haematopoietic stem cell transplantation using unrelated donors / M. Remberger [et al.] // Bone Marrow Transplant. – 2002. – Vol. 30, N 7. ‒ P. 761–768. https://doi.org/10.1038/sj.bmt.1703735
17. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial / F. Locatelli [et al.] // Blood. ‒ 2000. ‒ Vol. 95, N 5. ‒ P. 1572‒1579. https://doi.org/10.1182/blood.v95.5.1572.005k12_1572_1579
18. Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival / A. Gustafsson Jernberg [et al.] // Bone Marrow Transplant. ‒ 2003. ‒ Vol. 31 (3). ‒ P. 175‒181. https://doi.org/10.1038/sj.bmt.1703808
19. Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: Higher CD34+ cell doses are associated with decreased relapse rates / R. Nakamura [et al.] // Biol. Blood Marrow Transplant. – 2008. – Vol. 14, N 4. ‒ P. 449–457. https://doi.org/10.1016/j.bbmt.2008.02.005
20. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose / M. A. Pulsipher [et al.] // Blood. – 2009. – Vol. 114, N 3. ‒ P. 2606–2616. https://doi.org/10.1182/blood-2009-03-208355
21. Higher CD34+ and CD3+ cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children / K. Kałwak [et al.] // Biol. Blood Marrow Transplant. – 2010. – Vol. 16, N 10. ‒ P. 1388–1401. https://doi.org/10.1016/j.bbmt.2010.04.001
22. Risk factors and timing of relapse after allogeneic transplantation in Pediatric ALL: for whom and when should interventions be tested? / M. A. Pulsipher [et al.] // Bone Marrow Transplant. – 2015. – Vol. 50, N 9. ‒ P. 1173–1179. https://doi.org/10.1038/bmt.2015.103
23. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group / P. Bader [et al.] // J. Clin. Oncol. – 2009. – Vol. 27, N 3. ‒ P. 377–384. https://doi.org/10.1200/JCO.2008.17.6065
24. Minimal residual disease and childhood leukemia: standard of care recommendations from the Pediatric Oncology Group of Ontario MRD Working Group / U. H. Athale [et al.] // Pediatr. Blood Cancer. – 2016. – Vol. 63, N 6. ‒ P. 973–982. https://doi.org/10.1002/pbc.25939
25. Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy? ‒ A multicenter EBMT-PDWP study. A. Willasch [et al.] // Bone Marrow Transplant. ‒ 2020. ‒ Vol. 55, N 8. ‒ P. 1540–1551. https://doi.org/10.1038/s41409-020-0854-0
26. Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters / D. Bresters [et al.] // Bone Marrow Transplant. ‒ 2016. ‒ Vol. 51, N 11. ‒ P. 1482–1489. https://doi.org/10.1038/bmt.2016.139
27. State-of the-art fertility preservation in children and adolescents undergoing haematopoietic stem cell transplantation: a report on the expert meeting of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT) in Baden, Austria, 29‒30 September 2015 / J.-H. Dalle [et al.] // Bone Marrow Transplant. ‒ 2017. ‒ Vol. 52, N 7. ‒ P. 1029–1035. https://doi.org/10.1038/bmt.2017.21
28. Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children / M. M. Pfeiffer [et al.] // Haematologica. ‒ 2010. ‒ Vol. 95, N 8. ‒ P. 1381‒1388. https://doi.org/10.3324/haematol.2009.021121
29. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry / S. S. Farag [et al.] // Biol. Blood Marrow Transplant. ‒ 2006. ‒ Vol. 12, N 8. ‒ P. 876–884. https://doi.org/10.1016/j.bbmt.2006.05.007